Congress reports

Congress reports

Each memo inOncology SPECIAL ISSUE congress report delivers the latest in lung cancer research to come out of a major international oncology congress. Each issue is now translated into Chinese (Mandarin), Spanish, and Japanese. The next SPECIAL ISSUE report will summarise findings presented at the Annual Congress of the European Society for Medical Oncology (ESMO), October 2019.

Access Congress Reports here:

ASCO 2019





Expert interviews at ASCO 2019


Dr. Martin Reck gives an overview on where we are today regarding immunotherpaies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.

Dr Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future "predictive biomarker algorithm" in lung cancer might look like.

Dr. Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.

Dr. Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.

ELCC 2019

Expert interviews at ELCC 2019

Prof. Garrido gives an overview of the management of patients with stage III NSCLC, novel treatments in stage III disease and recent insights concerning immune modulatory vaccination in patients with NSCLC.

Dr. Newsom-Davis on the treatment algorithm for ALK-positive NSCLC and future developments for patients with ALK/ROS1-positive tumors.

Prof. Peled talks about the importance of early detection of lung cancer – especially in poorer countries –, promising biomarkers for the early detection and new insights into the interactions between lung cancer cells and the tumor microenvironment.

Prof. Dingemans explains the importance of chemotherapy in the current management of NSCLC and promising new combinations of chemotherapeutic agents with other drug classes.

ESMO 2018




Expert interviews at ESMO


Dr. Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.

Dr. Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.

WCLC 2018





Expert interviews at WCLC 2018


Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using EGFR-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

Virote Sriuranpong talks about new agents in the area of EGFR-targeted therapy as well as the results obtained with afatinib in a named patient program at Asian centers.

ASCO 2018

Expert interviews at ASCO 2018


Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Terufumi Kato talks about the nationwide screening project LC-SCRUM-Japan and the insights that have been obtained through these data in general and regarding squamous-cell lung cancer in particular.

WCLC 2017

Expert interviews at WCLC

IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.

ESMO 2017

Expert interviews at ESMO


Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.

ASCO 2017

Expert interviews at ASCO

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options

WCLC 2016

Expert interviews at WCLC

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

James Chih-Hsin Yang talks TKIs